Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias (AVATAR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
AR
-
Arezzo, AR, Italy, 52100
- Recruiting
- Cardiovascular Department, Ospedale S.Donato
-
Contact:
- Pasquale Notarstefano, MD
- Email: notarstefano2001@yahoo.it
-
Principal Investigator:
- Leonardo Bolognese, MD, FESC
-
Principal Investigator:
- Pasquale Notarstefano, MD
-
Sub-Investigator:
- Simone Grotti
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. presence of ventricular ectopic beats (VEB) with left-bundle-branch block morphology or right-bundle-branch block morphology and positive concordance throughout the chest leads, inferior axis and at least one of the following:
- >2000 isolated VEB/24h
- symptomatic monomorphic ventricular tachycardia
- left ventricular disfunction supposed to be due to tachycardia-induced cardiomyopathy
Exclusion Criteria:
- known structural heart disease
- pregnancy
- life expectancy < 1 year
Study Plan
How is the study designed?
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Antiarrhythmic drugs
Flecainide or Propafenone or Sotalol (oral, standard dosage)
|
|
|
Experimental: ABLATION
Catheter Ablation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SF-36 score
Time Frame: 6 months
|
Quality of life improvement according to SF-36 score variations
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Cardiac Complexes, Premature
- Tachycardia
- Tachycardia, Ventricular
- Ventricular Premature Complexes
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Membrane Transport Modulators
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Sympatholytics
- Flecainide
- Sotalol
- Anti-Arrhythmia Agents
- Propafenone
Other Study ID Numbers
Other Study ID Numbers
- Arezzo008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.